Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

DNA methylation profiling in colon cancer

ABSTRACT: Profiling of CpG island methylation in 19 primary colon cancer and paired normal samples Agilent 244k CpG island microarray

ORGANISM(S): Homo sapiens

SUBMITTER: Eddy van Roon

PROVIDER: E-GEOD-39334 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer.

van Roon Eddy H EH Boot Arnoud A Dihal Ashwin A AA Ernst Robert F RF van Wezel Tom T Morreau Hans H Boer Judith M JM

Clinical epigenetics 20130116 1

<h4>Background</h4>Cancer-specific hypermethylation of (promoter) CpG islands is common during the tumorigenesis of colon cancer. Although associations between certain genetic aberrations, such as BRAF mutation and microsatellite instability, and the CpG island methylator phenotype (CIMP), have been found, the mechanisms by which these associations are established are still unclear. We studied genome-wide DNA methylation differences between colorectal tumors carrying a BRAF mutation and BRAF wil ...[more]

PMID: 23324568

Similar Datasets

Project description:Genome wide methylation profiling of gliomas is likely to provide important clues to improving treatment outcomes. Restriction enzyme based approaches have been widely utilized for methylation profiling of cancer genomes and will continue to have importance in combination with higher density microarrays. With the availability of the human genome sequence and microarray probe sequences, these approaches can be readily characterized and optimized via in silico modeling. We adapted the previously described HpaII/MspI based Methylation Sensitive Restriction Enzyme (MSRE) assay for use with two-color Agilent 244K CpG island microarrays. In this assay, fragmented genomic DNA is digested in separate reactions with isoschizomeric HpaII (methylation-sensitive) and MspI (methylation-insensitive) restriction enzymes. Using in silico hybridization, we found that genomic fragmentation with BfaI was superior to MseI, providing a maximum effective coverage of 22,362 CpG islands in the human genome. In addition, we confirmed the presence of an internal control group of fragments lacking HpaII/MspI sites which enable separation of methylated and unmethylated fragments. We used this method on genomic DNA isolated from normal brain, U87MG cells, and a glioblastoma patient tumor sample and confirmed selected differentially methylated CpG islands using bisulfite sequencing. Along with additional validation points, we performed a receiver operating characteristics (ROC) analysis to determine the optimal threshold (p â¤ 0.001). Based on this threshold, we identified ~2400 CpG islands common to all three samples and 145 CpG islands unique to glioblastoma. These data provide general guidance to individuals seeking to maximize effective coverage using restriction enzyme based methylation profiling approaches. Five samples: normal human brain DNA, U87MG cell line, glioblastoma tumor, human DNA treated with SssI enzyme used as positive control, and Genomiphied human DNA used as negative control. Two technical replicates were performed on all samples except the negative control.

Dataset Information

DNA methylation profiling in colon cancer

Publications

BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets